Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cabaletta Bio ( (CABA) ) has shared an announcement.
On October 9, 2025, Cabaletta Bio presented new clinical and translational data from its RESET-PV trial at the 2025 ESGCT Annual Congress. The trial evaluates rese-cel without preconditioning in patients with pemphigus vulgaris, showing promising results such as complete B cell depletion and early clinical responses. The data suggest that rese-cel could offer a simplified treatment regimen, potentially expanding access to patients seeking alternatives without preconditioning. The company plans to expand patient enrollment and explore higher doses, while considering the removal of preconditioning in other trials within the RESET program.
The most recent analyst rating on (CABA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.
Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on developing curative targeted cell therapies specifically for patients with autoimmune diseases. The company is advancing the discovery and development of engineered T cell therapies, with its lead product being rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Cabaletta Bio is headquartered in Philadelphia, PA.
Average Trading Volume: 1,669,623
Technical Sentiment Signal: Hold
Current Market Cap: $212.2M
See more insights into CABA stock on TipRanks’ Stock Analysis page.